Skba Capital Management LLC Raises Holdings in Gilead Sciences, Inc. (GILD)
Skba Capital Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,500 shares of the biopharmaceutical company’s stock after purchasing an additional 35,900 shares during the quarter. Skba Capital Management LLC’s holdings in Gilead Sciences were worth $10,086,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Seizert Capital Partners LLC grew its position in Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Investment Centers of America Inc. grew its position in Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares during the last quarter. Fagan Associates Inc. grew its position in Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 845 shares during the last quarter. Capital Asset Advisory Services LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $875,000. Finally, First PREMIER Bank grew its position in Gilead Sciences by 9.0% during the 2nd quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after purchasing an additional 1,787 shares during the last quarter. Institutional investors and hedge funds own 74.62% of the company’s stock.
In other news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 666,819 shares of company stock worth $52,303,086. Insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Skba Capital Management LLC Raises Holdings in Gilead Sciences, Inc. (GILD)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dailypolitical.com/2017/11/17/skba-capital-management-llc-raises-holdings-in-gilead-sciences-inc-gild.html.
Shares of Gilead Sciences, Inc. (GILD) opened at $72.41 on Friday. The company has a market capitalization of $93,803.18, a P/E ratio of 7.50, a P/E/G ratio of -1.20 and a beta of 1.13. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 earnings per share. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. equities analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
GILD has been the topic of a number of recent analyst reports. BMO Capital Markets reaffirmed a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price target on the stock in a report on Wednesday, September 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $84.87.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.